Stock Price Quote

MEDICO REMEDIES LTD.

NSE : MEDICOBSE : 540937ISIN CODE : INE630Y01024Industry : Pharmaceuticals & DrugsHouse : Private
BSE45.560.53 (+1.18 %)
PREV CLOSE ( ) 45.03
OPEN PRICE ( ) 44.13
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 150918
TODAY'S LOW / HIGH ( )44.13 47.57
52 WK LOW / HIGH ( )35 79.78
NSE45.620.74 (+1.65 %)
PREV CLOSE( ) 44.88
OPEN PRICE ( ) 44.88
BID PRICE (QTY) 45.62 (507)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3567824
TODAY'S LOW / HIGH( ) 43.80 47.69
52 WK LOW / HIGH ( )34.8 79.83
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 18-03 1994
Management Info
Haresh Mehta - Chairman Harshit Mehta - Managing Director
Registered Office

Address 1105/1106, 11th Floor,Hubtown Solaris, Opp Telli Galli,N S Phadke Marg, Andheri (East) ,
Mumbai,
Maharashtra-400069

Phone 022 26821054 / 1055 / 26837116

Email medicoremedies@yahoo.com / info@medicoremedies.com

Website www.medicoremediesindia.com / www.medicoremediesindia.net / www.tabletandcapsules.com

Registrars Details
Cameo Corporate Services Ltd
304 Sai Sadan 3rd Floor,76 - 78 Mody Street,Fort,Mumbai
Listing : BSE, NSE

NEWS

11Mar Medico Remedies informs about disclosure
Medico Remedies has informed that the exchange has received the disclosu..
05Mar Medico Remedies informs about disclosu
Medico Remedies has informed that the Exchange has received the disclosu..
28Feb Medico Remedies leads the gainers of g
Medico Remedies is currently trading at Rs. 55.18, up by 4.48 points or..
20Feb Medico Remedies informs about disclosu
Medico Remedies has informed that the Exchange has received the disclosu..
07Feb Medico Remedies informs about press re
Medico Remedies has informed that it enclosed the newspaper advertisemen..

Financials

in Millions
QTR Dec 24 ANNUAL 24
Net Profit26.1982.9100000000001
Gross Profit 34.97 113.35
Operating Profit 45.37150.38
Net Sales 394.91449.21

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE)
peergroup  12021.95 (6.68%)
M.Cap ( in Cr)15424.03
Astrazeneca Pharma I (BSE)
peergroup  8493.90 (1.43%)
M.Cap ( in Cr)21234.75
Eris Lifesciences (BSE)
peergroup  1407.80 (7.29%)
M.Cap ( in Cr)19168.97
Kwality Pharma (BSE)
peergroup  873.50 (8.28%)
M.Cap ( in Cr)906.36
Alivus Life Sciences (BSE)
peergroup  1066.80 (6.15%)
M.Cap ( in Cr)13072.25

Shareholding Pattern

PROMOTERS 66.83%
NON-INSTITUTION 32%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Medico Remedies Ltd.

Medico Remedies Ltd. was incorporated in the year 1994. Its today's share price is 45.56. Its current market capitalisation stands at Rs 378.08 Cr. In the latest quarter, company has reported Gross Sales of Rs. 1449.21 Cr and Total Income of Rs.1470.49 Cr. The company's management includes Anuj Mody, Hasan Bohra, Kunal Tushar Vora, Dayanand Shivshankar Mathapati, Deepesh Shah, Bharat Rathod, Deepak Vekaria, Rita Mehta, Rishit Mehta, Harshit Mehta, Haresh Mehta.

It is listed on the BSE with a BSE Code of 540937 , NSE with an NSE Symbol of MEDICO and ISIN of INE630Y01024. It's Registered office is at 1105/1106, 11th Floor,Hubtown Solaris, Opp Telli Galli,N S Phadke Marg, Andheri (East) Mumbai-400069, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Pratap R Rajwade, VJ Shah & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.